Total Payments
$40,470
2021 Payments
$1,250
Companies
6
Transactions
20
Medicare Patients
19,244
Medicare Billing
$21.7M
Payment Breakdown by Category
Consulting$26,459 (65.4%)
Other$8,500 (21.0%)
Research$2,500 (6.2%)
Travel$2,476 (6.1%)
Food & Beverage$534.25 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $26,459 | 6 | 65.4% |
| Grant | $8,500 | 1 | 21.0% |
| Unspecified | $2,500 | 2 | 6.2% |
| Travel and Lodging | $2,476 | 5 | 6.1% |
| Food and Beverage | $534.25 | 6 | 1.3% |
Payments by Type
General
$37,970
18 transactions
Research
$2,500
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $16,127 | 10 | $0 (2018) |
| Alcon Vision LLC | $8,500 | 1 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $6,650 | 1 | $0 (2018) |
| Genentech USA, Inc. | $6,516 | 5 | $0 (2017) |
| Digital Diagnostics Inc. | $2,500 | 2 | $0 (2021) |
| Heidelberg Engineering, Inc. | $176.88 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $1,250 | 1 | Digital Diagnostics Inc. ($1,250) |
| 2020 | $1,250 | 1 | Digital Diagnostics Inc. ($1,250) |
| 2019 | $8,500 | 1 | Alcon Vision LLC ($8,500) |
| 2018 | $11,821 | 4 | Novartis Pharmaceuticals Corporation ($6,650) |
| 2017 | $17,649 | 13 | Regeneron Healthcare Solutions, Inc. ($10,956) |
All Payment Transactions
20 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/05/2021 | Digital Diagnostics Inc. | IDX-DR (Device) | — | Cash or cash equivalent | $1,250.00 | Research |
| Study: IDx-DR • Category: Diagnostic Device | ||||||
| 09/16/2020 | Digital Diagnostics Inc. | IDx-DR (Device) | — | Cash or cash equivalent | $1,250.00 | Research |
| Study: UPenn study • Category: Diagnostic Device | ||||||
| 10/09/2019 | Alcon Vision LLC | — | Grant | Cash or cash equivalent | $8,500.00 | General |
| 12/12/2018 | Regeneron Healthcare Solutions, Inc. | EYLEA AFLIBERCEPT INJECTION (Biological) | Consulting Fee | Cash or cash equivalent | $4,080.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/12/2018 | Regeneron Healthcare Solutions, Inc. | EYLEA AFLIBERCEPT INJECTION (Biological) | Food and Beverage | In-kind items and services | $70.59 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/20/2018 | Regeneron Healthcare Solutions, Inc. | EYLEA AFLIBERCEPT INJECTION (Biological) | Consulting Fee | Cash or cash equivalent | $1,020.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/03/2018 | Novartis Pharmaceuticals Corporation | BROLUCIZUMAB (Drug) | Consulting Fee | Cash or cash equivalent | $6,650.00 | General |
| 12/20/2017 | Regeneron Healthcare Solutions, Inc. | EYLEA AFLIBERCEPT INJECTION (Biological) | Consulting Fee | Cash or cash equivalent | $1,022.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/07/2017 | Regeneron Healthcare Solutions, Inc. | EYLEA AFLIBERCEPT INJECTION (Biological) | Consulting Fee | Cash or cash equivalent | $8,687.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/07/2017 | Regeneron Healthcare Solutions, Inc. | EYLEA AFLIBERCEPT INJECTION (Biological) | Travel and Lodging | In-kind items and services | $828.57 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/07/2017 | Regeneron Healthcare Solutions, Inc. | EYLEA AFLIBERCEPT INJECTION (Biological) | Travel and Lodging | In-kind items and services | $270.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 06/14/2017 | Regeneron Healthcare Solutions, Inc. | EYLEA AFLIBERCEPT INJECTION (Biological) | Food and Beverage | In-kind items and services | $81.63 | General |
| Category: OPHTHALMOLOGY | ||||||
| 06/14/2017 | Regeneron Healthcare Solutions, Inc. | EYLEA AFLIBERCEPT INJECTION (Biological) | Food and Beverage | In-kind items and services | $48.78 | General |
| Category: OPHTHALMOLOGY | ||||||
| 06/14/2017 | Regeneron Healthcare Solutions, Inc. | EYLEA AFLIBERCEPT INJECTION (Biological) | Food and Beverage | In-kind items and services | $17.99 | General |
| Category: OPHTHALMOLOGY | ||||||
| 06/02/2017 | Genentech USA, Inc. | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $138.38 | General |
| Category: None | ||||||
| 06/01/2017 | Genentech USA, Inc. | Non-Covered Product (Drug) | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| Category: None | ||||||
| 06/01/2017 | Genentech USA, Inc. | Non-Covered Product (Drug) | Travel and Lodging | In-kind items and services | $836.90 | General |
| Category: None | ||||||
| 06/01/2017 | Genentech USA, Inc. | Non-Covered Product (Drug) | Travel and Lodging | In-kind items and services | $472.50 | General |
| Category: None | ||||||
| 06/01/2017 | Genentech USA, Inc. | Non-Covered Product (Drug) | Travel and Lodging | Cash or cash equivalent | $68.33 | General |
| Category: None | ||||||
| 01/18/2017 | Heidelberg Engineering, Inc. | Spectralis (Device) | Food and Beverage | In-kind items and services | $176.88 | General |
| Category: Ophthalmology Imaging Equipment | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| IDx-DR | Digital Diagnostics Inc. | $1,250 | 1 |
| UPenn study | Digital Diagnostics Inc. | $1,250 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 25 | 4,793 | 25,930 | $21.0M | $5.5M |
| 2022 | 20 | 4,407 | 24,014 | $14.1M | $5.4M |
| 2021 | 22 | 4,956 | 28,228 | $10.1M | $5.5M |
| 2020 | 19 | 5,088 | 27,898 | $9.5M | $5.3M |
Total Patients
19,244
Total Services
106,070
Medicare Billing
$21.7M
Procedure Codes
86
All Medicare Procedures & Services
86 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 312 | 3,060 | $9.0M | $2.1M | 23.4% |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 2023 | 350 | 8,034 | $4.5M | $1.7M | 38.8% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 134 | 1,811 | $1.5M | $327,634 | 21.4% |
| 67028 | Injection of drug into eye | Office | 2023 | 667 | 3,337 | $2.3M | $316,370 | 13.9% |
| J3490 | Unclassified drugs | Office | 2023 | 38 | 132 | $587,400 | $210,448 | 35.8% |
| J3590 | Unclassified biologics | Office | 2023 | 100 | 769 | $520,800 | $182,552 | 35.1% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 34 | 1,170 | $347,490 | $140,822 | 40.5% |
| 92134 | Imaging of retina | Office | 2023 | 1,220 | 4,425 | $725,700 | $131,150 | 18.1% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 626 | 1,367 | $486,652 | $92,178 | 18.9% |
| Q5124 | Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | Office | 2023 | 56 | 315 | $176,400 | $55,114 | 31.2% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 462 | 562 | $283,248 | $50,272 | 17.7% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 204 | 207 | $97,497 | $22,475 | 23.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 144 | 144 | $93,744 | $16,329 | 17.4% |
| 67041 | Removal of membrane of retina | Facility | 2023 | 15 | 15 | $66,555 | $13,452 | 20.2% |
| 67210 | Destruction of growth of retina using a laser | Office | 2023 | 19 | 29 | $58,696 | $11,368 | 19.4% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 99 | 99 | $59,202 | $10,510 | 17.8% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 64 | 157 | $39,500 | $8,444 | 21.4% |
| 67145 | Photocoagulation treatment to prevent detachment of retina | Office | 2023 | 25 | 25 | $51,750 | $4,851 | 9.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 76 | 76 | $27,056 | $3,945 | 14.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 40 | 41 | $20,787 | $3,443 | 16.6% |
| 67515 | Injection of drug or substance into membrane covering eyeball | Office | 2023 | 15 | 34 | $6,766 | $1,349 | 19.9% |
| 92020 | Exam of the internal drainage system of eye | Office | 2023 | 46 | 50 | $5,550 | $959.92 | 17.3% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 21 | 26 | $5,096 | $932.23 | 18.3% |
| 92250 | Photography of the retina | Office | 2023 | 11 | 11 | $1,727 | $275.00 | 15.9% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 15 | 34 | $2,210 | $27.75 | 1.3% |
About Dr. David Williams, MD
Dr. David Williams, MD is a Retina Specialist healthcare provider based in Baxter, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1558359554.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Williams, MD has received a total of $40,470 in payments from pharmaceutical and medical device companies, with $1,250 received in 2021. These payments were reported across 20 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($26,459).
As a Medicare-enrolled provider, Williams has provided services to 19,244 Medicare beneficiaries, totaling 106,070 services with total Medicare billing of $21.7M. Data is available for 4 years (2020–2023), covering 86 distinct procedure/service records.
Ad
Practice Information
- Specialty Retina Specialist
- Other Specialties Ophthalmology
- Location Baxter, MN
- Active Since 10/12/2005
- Last Updated 12/03/2025
- Taxonomy Code 207WX0107X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1558359554
Products in Payments
- EYLEA AFLIBERCEPT INJECTION (Biological) $16,127
- BROLUCIZUMAB (Drug) $6,650
- Non-Covered Product (Drug) $6,516
- IDX-DR (Device) $1,250
- IDx-DR (Device) $1,250
- Spectralis (Device) $176.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.